Officials at Charles River Laboratories International say the company has acquired Agilux Laboratories, a CRO that offers integrated discovery small- and large-molecule bioanalytical services, as well as drug metabolism, pharmacokinetic, and pharmacology services. The purchase price was $64 million in cash.
The addition of Agilux is complementary to Charles River’s existing nonclinical portfolio, noted a Charles River spokesperson. Providing a more comprehensive service offering will improve the efficiency of clients’ early-stage research efforts by enabling them to transition their drug candidates seamlessly through the discovery and safety assessment process, according to James C. Foster, chairman, president, and CEO of Charles River. He added that the acquisition of Agilux enhances Charles River's ability to work with clients earlier in the drug research process and maintain the relationship as molecules progress through nonclinical development.
“The acquisition of Agilux Laboratories supports Charles River’s strategy to offer clients a broader, integrated portfolio that enables them to work with us continuously from the earliest stages of drug research through the nonclinical development process,” he said. “Agilux reinforces the linkage between our discovery and safety assessment capabilities, and provides clients with a comprehensive testing solution that spans their discovery and regulated drug development needs. We expect to leverage Agilux’s strong client relationships in the Boston–Cambridge biohub, one of the most significant concentrations of medical research in the world, and expand the reach of its discovery bioanalytical services offering to Charles River’s global client base.”